key: cord-0700697-4wou6s93
authors: West, James Lee; Nutting, Andrew; Daughtry, Brock; Frey, Andrew M.; Nicolas, Clara T.; Saab, Rayan; Sibley, David H.; Smith, Joshua; Roan, Ronald; Crain, Michael
title: Coronavirus 2019 (COVID‐19) venovenous extracorporeal oxygenation: Single community hospital results and insights
date: 2022-04-19
journal: J Card Surg
DOI: 10.1111/jocs.16514
sha: f87fed004d4c091086d94df4e2d5950cab3bfa1f
doc_id: 700697
cord_uid: 4wou6s93

BACKGROUND: The role of extracorporeal membrane oxygenation (ECMO) for patients with refractory respiratory failure due to coronavirus 2019 (COVID‐19) is still unclear even now over a year into the pandemic. ECMO is becoming more commonplace even at smaller community hospitals. While the advantages of venovenous (VV) ECMO in acute respiratory distress syndrome (ARDS) from COVID‐19 have not been fully determined, we believe the benefits outweighed the risks in our patient population. Here we describe all patients who underwent VV ECMO at our center. METHODS: All patients placed on ECMO at our center since the beginning of the pandemic, May 5, 2020, until February 20, 2021 were included in our study. All patients placed on ECMO during the time period described above were followed until discharge or death. The primary endpoint was in‐hospital death. Secondary outcomes included discharge disposition, that is, whether patients were sent to a long‐term acute care center (LTAC), inpatient rehabilitation, or went directly home. RESULTS: A total of 41 patients were placed on VV ECMO for refractory acute respiratory failure. Survival to discharge, the primary end point, was 63.4% (26/41). Inpatient mortality was 36.6% (15/41). CONCLUSIONS: We show here that a successful high‐volume VV ECMO program for ARDS is achievable at even a medium‐size community hospital. We think our success can be replicated by most small‐ and medium‐size community hospitals with cardiothoracic surgery programs and intensivist teams.

| 1 ECMO is becoming more commonplace even at smaller community hospitals. 4 The Conventional Ventilatory Support versus Extracorporeal Membrane Oxygenation for Severe Adult Respiratory Failure (CESAR) trial has demonstrated the improvement in mortality in patients referred to an ECMO center. 5 While the advantages of VV ECMO in ARDS from COVID-19 have not been fully determined, we believe the benefits outweighed the risks in our patient population.

Here we describe all patients who underwent VV ECMO at our center.

All patients placed on ECMO at our center since the beginning of the pandemic, May 5, 2020 until February 20, 2021 were included in our study. All patients were followed until discharge or mortality. All patients were confirmed SARS-CoV-2-positive by laboratory testing and were in acute respiratory failure. Patients were managed by a multidisciplinary team including anesthesiologists/critical care intensivists, cardiologists, pharmacists, and cardiothoracic surgeons. The study was approved by our institutional review board.

The primary endpoint was in-hospital death. All patients placed on ECMO during the time period described above were followed until discharge or death. Secondary outcomes included discharge disposition, that is, whether patients were sent to a long-term acute care center (LTAC), inpatient rehabilitation, or went directly home. We report hospital length of stay, duration of mechanical ventilation, duration of ECMO, tracheostomy use, need for renal replacement therapy, and complications while on ECMO.

Continuous variables were presented as median with interquartile range (IQR) or mean with standard deviation. However, due to outliers, we believe the central tendency of our data is most accurately reflected by median with IQR. Categorical variables were presented as proportions.

From May 5, 2020 to February 20, 2021, a total of 41 patients were placed on VV ECMO for refractory acute respiratory failure.

Pre-ECMO course and patient characteristics are summarized in 

Any bleeding that required at least temporary cessation of anticoagulation was recorded as a bleeding event. Eighteen patients had bleeding events (43.9%). Two patients had hemorrhagic brain injuries diagnosed with CT imaging; both patients died. Nine patients had significant cannula site bleeding that required at least temporary cessation of anticoagulation. Three patients had gastrointestinal bleeding that required transfusion. Eleven patients were switched from heparin to argatroban due to thrombocytopenia. One patient suffered a dislodgement of their dual lumen single right IJ cannula and was emergently converted to femoral−femoral configuration. We present one of the largest cohorts of patients with refractory COVID-19 requiring ECMO cannulation at a nonacademic mediumsize (less than 500 available beds) hospital. While the role of ECMO remains unclear for patients with refractory respiratory failure from COVID-19, we believe our patient population benefited from it.

Our mortality rate was substantially lower than the most recent COVID-19 ECMO mortality from the Extracorporeal Life Support Organization (ELSO) registry. 7 Our mortality rate was also lower than the prepandemic ECMO for ARDS mortality from ELSO, which was approximately 40%. 3 We believe one of the main contributing factors to our success was early cannulation in the ARDS course. Originally most of the patients were cannulated with bilateral femoral cannulas. As the pandemic progressed, we started using more dual-lumen single-cannula right ventricular assist devices (right atrium to pulmonary artery) in the right IJ vein using the ProtekDuo system (TandemLife). We had good results from the dual-lumen single-cannula right ventricular assist device, and we believe it is more comfortable for the patient and allows for ambulation. The dual-lumen single-cannula right ventricular assist device also provides right-sided support in cases of right ventricular dysfunction and potentially decreases recirculation issues. ELSO guidelines in 2020 recommended against a single right IJ cannula. 9 However, the ELSO 2021 guidelines changed to more friendly language, saying there "may be a role" for these cannulas. 3 We successfully cannulated 17 patients at bedside, a safe method that has been previously discussed in the literature. 2 was not considered a contraindication to cannulation, even though a BMI greater than 40 is listed as a relative contraindication in the ELSO guidelines. 9 We cannulated 14 patients with a BMI above 40. The mortality in our morbidly obese cohort was 5/14 (35.7%). We believe this vulnerable patient population can benefit greatly from ECMO as traditional mechanical ventilatory strategies are less effective in the morbidly obese due to decreased lung compliance and decreased forced expiratory volumes. 10 Therefore, we believe that extracorporeal oxygenation is even more important in an obese patient with ARDS. We do acknowledge the obvious technical challenges of cannulating obese patients. However, we have demonstrated that this can be done safely at the bedside in crowded ICU rooms. Our most obese patient, with a BMI of 81, was cannulated at bedside.

We did not prone patients while cannulated on ECMO due to the logistical challenges proning while cannulated involves, although there is some limited literature now available showing the feasibility and benefits of proning while cannulated. 11, 12 Furthermore, a substantial portion of our patients were obese, adding to these technical challenges. We did ambulate several patients with single right IJ dual-lumen cannulas. We believe ambulation has similar advantages of recruiting unused alveoli and increases lung compliance. 13 We extubated 12 patients while on ECMO. We believe extubation decreases invasive ventilation injury, increases patient involvement in pulmonary toilette, and promotes easier ambulation.

Four patients that were extubated on ECMO required reintubation, and all four patients requiring reintubation while on ECMO eventually died. 4 showed in their prepandemic analysis that small-and medium-size hospital ECMO programs had a statistically significant lower mortality in these patients. Our mortality was considerably lower than the predicted survival of ventilated COVID-19 patients. [15] [16] [17] Although the role of ECMO in patients with COVID-19 has still not been established, we believe our cannulated patients were unlikely to survive without ECMO support. Our mortality was lower than national trends despite a patient population that was older, more obese, and therefore at a higher risk for death from COVID-19 infection. We show here that a successful high-volume WEST ET AL. 

Informed patient consent statement is not available since our study was a retrospective review of results. The study was approved by our Institutional Review Board.

James Lee West http://orcid.org/0000-0001-9728-1192

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Venovenous extracorporeal membrane oxygenation for patients with refractory coronavirus disease 2019 (COVID-19): multicenter experience of referral hospitals in a large health care system

Extracorporeal membrane oxygenation for COVID-19: updated 2021 guidelines from the Extracorporeal Life Support Organization

Trends in mortality and resource utilization for extracorporeal membrane oxygenation in the United States

Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial

Acute respiratory distress syndrome: the Berlin Definition

Full COVID-19 Registry Dashboard

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim Guidelines: a consensus document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers

The effect of obesity on lung function

Prone positioning during venovenous extracorporeal membrane oxygenation in acute respiratory distress syndrome. A multicenter cohort study and propensity-matched analysis

Prone positioning under VV-ECMO in SARS-CoV-2-induced acute respiratory distress syndrome

The effect of body position on pulmonary function: a systematic review

Outcome and cost of nurse-led versus perfusionist-led extracorporeal membrane oxygenation

Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. A meta-analysis

Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: a multicentric study in Germany

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area